Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

14.30
-0.5500-3.70%
Post-market: 14.300.00000.00%16:10 EDT
Volume:485.38K
Turnover:6.98M
Market Cap:1.51B
PE:-9.22
High:14.86
Open:14.86
Low:14.21
Close:14.85
52wk High:38.12
52wk Low:10.60
Shares:105.35M
Float Shares:60.53M
Volume Ratio:0.82
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5508
EPS(LYR):-1.4480
ROE:-27.41%
ROA:-19.06%
PB:2.56
PE(LYR):-9.88

Loading ...

Edgewise Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 19

Will Edgewise Therapeutics’ (EWTX) Rising Losses Reshape Its Long-Term Investment Strategy?

Simply Wall St.
·
Aug 15

Chief Business Officer Behrad Derakhshan Reports Disposal of Common Shares of Edgewise Therapeutics Inc

Reuters
·
Aug 15

Russell Alan J, Beneficial Owner, Reports Disposal of Edgewise Therapeutics Inc. Common Shares

Reuters
·
Aug 15

Kevin Koch, President and CEO, Reports Disposal of Common Shares of Edgewise Therapeutics Inc

Reuters
·
Aug 15

Joanne M. Donovan, CMO, Reports Disposal of Common Shares of Edgewise Therapeutics Inc

Reuters
·
Aug 15

Edgewise Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 09

Edgewise Therapeutics (EWTX) Gets a Buy from RBC Capital

TIPRANKS
·
Aug 08

Edgewise Therapeutics (EWTX) Receives a Buy from Evercore ISI

TIPRANKS
·
Aug 08

Raymond James Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)

TIPRANKS
·
Aug 08

Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating

TIPRANKS
·
Aug 07

Edgewise Therapeutics Reports Q2 2025 Net Loss of $36.1M, EPS at $0.34, Down from Previous Quarter

Reuters
·
Aug 07

BRIEF-Edgewise Therapeutics Q2 Operating Income USD -42.61 Million

Reuters
·
Aug 07

Edgewise Therapeutics Inc - Expects Cirrus-HCM Trial Update in Q4 2025

THOMSON REUTERS
·
Aug 07

Edgewise Therapeutics Announces Inducement Stock Options and RSU Awards for New Employees Under 2024 Equity Plan

Reuters
·
Aug 07

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Aug 07

Edgewise Therapeutics Inc : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $46

THOMSON REUTERS
·
Jul 30

Raymond James Initiates Edgewise Therapeutics at Strong Buy

MT Newswires Live
·
Jul 30

Edgewise Therapeutics initiated with a Strong Buy at Raymond James

TIPRANKS
·
Jul 30